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for	 genetic	 engineering	 was	 explored.	 This	 study	 proposes	 the	 engineering	 of	 S.	boulardii	 to	
overexpress	 and	 secrete	 therapeutic	 peptides	 such	 as	 interleukin‐10	 (IL‐10)	 and	 interleukin‐8	
(IL‐8).		The	probiotic	then	serves	as	a	transiently	colonizing	microbe,	allowing	direct	delivery	of	
therapeutic	 peptides	 to	 the	 intestine	 in	 high‐concentrations.	 Consequently,	 the	 recombinant	
probiotic	may	be	beneficial	over	current	oral	peptide	deliveries	or	treatments	for	Inflammatory	
Bowel	 Diseases.	 This	 study	 tests	 the	 probiotic’s	 ability	 to	 produce	 therapeutic	 peptides	 under	
control	of	regulatory	elements	from	the	closely	related	yeast	Saccharomyces	cerevisiae	(e.g.,	PYK1	
promoter,	 GAL1	 promoter,	 and	MAT	secretion	 signal).	 To	 demonstrate	 proper	 processing	 in	
yeast,	 the	 model	 S.	 cerevisiae	 was	 transformed	 with	 the	 IL‐10	 and	 IL‐8	 expressing	 plasmids.	
Western	Blots	showed	the	tagged	IL‐8	was	expressed	and	secreted	in	high	quantities,	with	one	
major	product	by	24	hours	after	 induction.	 In	 the	 first	construct,	 IL‐10	was	expressed,	but	not	
secreted.	 The	 ability	 for	 S.	 cerevisiae	 to	 express	 and/or	 secrete	 short,	 recombinant	 peptides	
suggests	 similar	 potential	 in	 the	 related	 S.	boulardii.	 An	 engineered	 strain	 of	 S.	boulardii	 was	
created	by	a	knocking	out	both	copies	of	 the	URA3	gene	using	homologous	recombination.	The	
expression,	secretion,	and	activity	of	IL‐8	and	IL‐10	will	be	tested	by	mass	spectrometry,	enzyme‐
linked	 immunosorbent	 assay	 (ELISA),	 and	a	 signalling	bioassay	 from	 J224	macrophages.	Given	
the	demonstration	 in	 transferred	vectors,	 a	delivery	 system	may	be	developed	by	 swapping	 in	
other	therapeutic	drugs	for	expression	in	S.	boulardii.  
 
 
